Novo Integrated Sciences Shares Surge 70% After Company Secures $78M Funding From HSBC For Acquisition Of Ophir Collection
Novo Integrated Sciences Shares Surge 70% After Company Secures $78M Funding From HSBC For Acquisition Of Ophir Collection
Novo Integrated Sciences (NASDAQ:NVOS) surged 70.29% in after-hours trading to $0.77 following HSBC's confirmation of a $78 million Standby Letter of Credit.
匯豐銀行確認了7800萬美元的備用信用證後，Novo Integrated Sciences（納斯達克股票代碼：NVOS）在盤後交易中飆升70.29％，至0.77美元。
What Happened: Novo Integrated Sciences has confirmed receiving written confirmation from HSBC for a Ready, Willing, and Able (RWA) issued for the delivery of a Standby Letter of Credit via Swift MT 760, according to a company press release filed with the SEC.
發生了什麼：Novo Integrated Sciences已確認收到匯豐銀行對通過Swift MT 760交付備用信用證簽發的Ready、Willing and Able（RWA）的書面確認， 根據 轉到向美國證券交易委員會提交的公司新聞稿。
This move is part of a program aimed at monetizing the SBLC, which is projected to provide the company with gross funding proceeds of approximately $78 million by Jun. 14.
此舉是旨在通過SBLC獲利的計劃的一部分，預計到6月14日，該計劃將爲該公司提供約7800萬美元的總融資收益。
The proceeds are intended to secure the closing of a previously disclosed Purchase and Sale Agreement to acquire the Ophir Collection, granting Novo sole ownership of this collection.
所得款項旨在確保先前披露的收購Ophir Collection的收購和銷售協議的完成，授予Novo對該藏品的唯一所有權。
The Ophir Collection refers to a specific collection of gemstones, with 43 gemstones in total, 42 of which are certified by the Gemological Institute of America.
Ophir 系列是指特定的寶石系列，共有 43 顆寶石，其中 42 顆獲得了美國寶石研究所的認證。
Novo's CEO Robert Mattacchione anticipates generating surplus cash through the Ophir Collection program, supporting non-dilutive financing for the company's growth objectives amid funding challenges faced by micro-cap companies.
Novo首席執行官羅伯特·馬塔基奧內預計，在微型股公司面臨資金挑戰的情況下，通過Ophir Collection計劃產生盈餘現金，爲公司的增長目標提供非稀釋性融資。
He said, "Our objective and focus on providing non-dilutive financing for the Company's growth objectives remains paramount. Specifically, both the Ophir Collection's monetizing potential together with the pending close of the previously disclosed $70 million SPA and Note with the RC Consulting Consortium Group, LLC will create the backstop necessary for the Company to pursue its' short and long-term global objectives."
他說：“我們的目標和重點仍然是爲公司的增長目標提供非稀釋性融資。具體而言，Ophir Collection的獲利潛力，以及先前披露的與RC諮詢聯盟集團有限責任公司簽訂的7,000萬美元SPA和票據的即將完成，都將爲公司實現其短期和長期全球目標提供必要的支持。”
Novo Integrated Sciences focuses on patient-centric healthcare solutions, integrating medical technology, advanced therapeutics, and rehabilitative science. Their approach aims to decentralize healthcare, enhancing patient-practitioner interactions and potentially reducing on-site medical center visits.
Novo Integrated Sciences專注於以患者爲中心的醫療保健解決方案，整合了醫療技術、先進療法和康復科學。他們的方法旨在分散醫療保健，增強患者與從業者的互動，並可能減少現場醫療中心的就診次數。
Price Action: NVOS closed at $0.45 on Thursday, showing a decrease of 0.84%. However, after hours, the stock surged to $0.77, marking an increase of 70.29%. Year to date, the stock has experienced a decrease of 41.43%, according to the data from Benzinga Pro.
價格走勢：NVOS週四收於0.45美元，下跌0.84％。但是，盤後該股飆升至0.77美元，漲幅爲70.29％。根據Benzinga Pro的數據，今年迄今爲止，該股已下跌了41.43％。
Image Via Shutterstock
圖片來自 Shutterstock
This story was generated using Benzinga Neuro and edited by Kaustubh Bagalkote
這個故事是使用 Benzinga Neuro 創作的，由 Kaustubh Bagalkote